After the onset of serious pneumococcal infections, patients are at a significantly increased risk of having a heart attack, according to a Vanderbilt study published in the journal Clinical ...

Since 1993 we have prospectively identified children with invasive infections caused by S. pneumoniae in the inpatient and outpatient setting at Texas Children's Hospital, Houston, TX. Pneumococci ...

Despite new diagnostic methods and expanded vaccination programs, many children in Uganda continue to suffer from severe brain infections, according to a new study from Karolinska Institutet. The ...

A new vaccine for pneumococcal disease will be tested under an international trial aiming to provide greater protection to babies against the common infection that causes pneumonia, sinusitis and ...

A study by Nongnooch Poowanawittayakom, MD, of the Infectious Diseases department at Washington University School of Medicine in St. Louis, Missouri, and colleagues, examined the medical records of ...

In a recent multicenter prospective study conducted at three hospitals in Tennessee and Georgia, including Vanderbilt University Medical Center, researchers at VUMC found a substantial burden of ...

The incidence of invasive pneumococcal disease, pneumonia, and otitis media peaked in infancy or early childhood, with pneumococcal disease rates being highest in the first year of life. Comorbidity ...

Are you at least 50 years old? The Center for Disease Control (CDC) now recommends you get vaccinated against pneumococcal diseases, a type of bacterial disease that can cause multiple illnesses. The ...

The Centers for Disease Control and Prevention has made a major change on age recommendations for a common vaccine. For the first time, the CDC said adults as young as 50 should get vaccinated against ...

A new study reveals how resistance to bacteraemic pneumonia is provided by a unique subset of lung T regulatory cells. A new study by University of Liverpool researchers reveals how resistance to ...

In young children, pneumococcal vaccine was found to reduce antibiotic-resistant infections by 62 percent, finds new study. The 13-valent pneumococcal conjugate vaccine (PCV13), first available in ...

Tuesday, Vaxcyte, Inc. (NASDAQ:PCVX) released topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the company's 31-valent pneumococcal conjugate ...